For type 2 diabetes mellitus. ANDA 209993, held by Qingdao Baheal Pharm. Metformin Hydrochloride.
As of Nov 16, 2026, ANDA 209993 (Metformin Hydrochloride), held by Qingdao Baheal Pharm, was first approved by FDA on Dec 27, 2018, with 1 approved supplement and 0 published complete response letters.
Metformin hydrochloride extended-release tablets are indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Dec 27, 2018 | Original application | Approved | None posted |
| Metformin Hydrochloride500MG · tablet, extended release;oral | Metformin Hydrochloride | Rx |
| Metformin Hydrochloride1GM · tablet, extended release;oral | Metformin Hydrochloride | Rx |
| Aug 11, 2026 | Supplement 3Labeling · Standard review | Approved | None posted |
| Dec 27, 2018 | Original application | Approved | None posted |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters